A cost-effectiveness analysis of baloxavir marboxil versus oseltamivir for seasonal influenza treatment in China
Baloxavir is a cost-effective alternative to oseltamivir for seasonal influenza treatment in China. It can improve patient outcomes and reduce influenza transmission at a societal level, offering value to the healthcare system.
Authors
- Han Jiang (ORCID: https://orcid.org/0000-0002-2928-8496)
- Yuekun Tang
- Fangyu Zheng
Institutions
- Fudan University (CN)
- Eye & ENT Hospital of Fudan University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.3389/fphar.2025.1697645
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00